Bringing the Next Generation of Oral Peptide Therapeutics to Patients

Pete Gough is Nimble’s Chief Scientific Officer where he leads the expansion of Nimble’s internal drug discovery capabilities, paving the way for development of our pipeline of proprietary therapeutics. Pete has 25+ years of experience in discovery research and a successful track record of driving varied research programs into clinical development.

Prior to joining Nimble, Pete served as CSO at Inzen Therapeutics, advancing the company from seed stage through Series B financing. Previously, Pete spent 15 years at GSK in roles of increasing responsibility. Most recently, he served as Head of the Hepatitis B Virus Discovery Performance Unit, leading GSK’s efforts to develop a functional cure for HBV, and earlier had led GSK’s discovery and development of a number of clinical assets across multiple therapeutic areas, including RIP1 kinase inhibitor GSK2982772 and STING agonist GSK3745417. Earlier in his career, Pete was a Research Assistant Professor at the University of Washington, and he received his D. Phil. and M. A. from the University of Oxford. Pete has authored/co-authored over 100 scientific articles and has been an invited speaker at numerous scientific conferences.

Away from work Pete enjoys spending time outdoors with his family and indulging in his passion for photography. He is an avid soccer fan and Everton supporter.

Brad Garcia is vice president of corporate development at Nimble Therapeutics. Brad brings more than 20 years of biotechnology and pharmaceutical experience to Nimble, where he currently leads corporate development, business operations, and finance.

Immediately before joining Nimble, he led the business development and commercialization activities for the peptide group at Roche, ultimately working to complete Nimble’s initial fundraising and spinout. Prior to Roche, Brad served in numerous scientific and business leadership roles at Agracetus (Monsanto Company), Pierce Biotechnology (Thermo Fisher Scientific), Gentel Biosciences (Intuitive Biosciences), and Primorigen Biosciences (Nucleus Biologics), and also provided business consulting services to his professional network. Brad received his undergraduate and graduate training from the University of Wisconsin, Madison, and has published in Nature Biotech, PNAS, Stem Cell Reports, among others.

Away from work, Brad enjoys traveling and spending time with family and friends, following Wisconsin Badger athletics and the Green Bay Packers (of course!), and embarking on culinary adventures.

Lauren Goodrich is vice president, head of platform at Nimble Therapeutics. Lauren leads a diverse team of scientists working to utilize Nimble’s proprietary maskless array synthesis technology for the discovery of peptide-based therapeutics. She is responsible for the ongoing success of external collaborations, Nimble’s internal pipeline, and further development of the platform.

Lauren earned a PhD in chemistry from the University of Michigan and a BS in chemistry from the University of Minnesota-Morris. After completing her graduate work, Lauren joined Roche as a postdoctoral fellow, where she focused on optimizing the synthesis of biopolymers on the company’s microarray platform. Lauren continued with Roche as a scientist in the technology innovation group, holding increasing levels of responsibility, and ultimately leading an interdisciplinary team to further advance the peptide microarray platform and its applications. Notably, Lauren and her team developed the latest generation peptide synthesizer, bioinformatic tools, and assays that Nimble continues to build upon for the rapid discovery of specific, high-affinity peptide ligands to proteins. She is an active member in the peptide therapeutics community, presenting at meetings and participating on scientific advisory committees, including the Boulder Peptide Society scientific advisory board.

Lauren enjoys spending time outdoors, tending to her vegetable garden, biking, and chasing her daughters around Madison’s beautiful parks. She’s an avid baker and an aspiring yogi.

Shelley Allen is vice president, head of drug discovery at Nimble Therapeutics where she is building drug discovery capabilities at the Philadelphia site to progress our internal pipeline.  Shelley has over 25 years of experience as a medicinal chemist and drug discovery leader, successfully driving several programs into the clinic.

Prior to joining Nimble, Shelley was VP, Medicinal Chemistry at Think Bioscience where she established drug discovery teams and capabilities to develop their internal programs. Previously, Shelley spent 22 years with Array Biopharma / Pfizer Boulder R&D, in roles of increasing responsibility where she contributed to the discovery of several clinical candidates and two approved drugs. As director of medicinal chemistry at Pfizer, she led programs from lead discovery to IND in the kinase area. Shelley began her career at Rhone-Poulenc Rorer after completing undergraduate studies at DeMontfort University of Leicester. She has published > 40 scientific papers and patents and is active in the American Chemical Society community.

Outside of work, Shelley enjoys being her daughter’s biggest cheerleader and enjoys travel, cooking and outdoor activities of all kinds. She is an avid swimmer, biker, rower and pickleball enthusiast.

Munir Mosaheb is vice president, head of Biology at Nimble Therapeutics, where he is building translational biology capabilities at the Philadelphia site to advance our internal pipeline. Munir has over 15+ years of experience in academia, biotech and pharmaceutical drug development, and has established himself as a leader in the immunology field, demonstrating expertise in both platform and program development and advancement towards IND.

Prior Nimble Therapeutics, Munir was the Head of Translational Biology and Immunology at Senda Biosciences (now Sail Biomedicines), where he founded and led Translational Biology team. Munir is renowned for his expertise in areas such as immunology, LNP technology, nucleic acid delivery, cell therapy and immunotherapy. He received his training in vaccinology from Merck & Co. and the Wetzler lab at BU, T cell biology from the Flavell lab at Yale, immuno-oncology and cell trafficking from the von Andrian lab at Harvard.

When he is not exploring the wild world of immunology, Munir enjoys spending time with his family, traveling, biking, swimming and inventing new recipes.